Researchers at the University of Tasmania have developed a portable diagnostic test that can detect DNA from the two transmissible cancers responsible for devil facial tumour disease, potentially improving disease surveillance in wild Tasmanian devil populations.
The test uses molecular technology to identify tumour DNA in samples collected from devils, with researchers successfully demonstrating its use under field conditions. Unlike existing laboratory-based molecular tests, the new method can be performed using portable equipment, allowing results to be obtained without first transporting samples to a laboratory.
The findings, published on 11 November 2026 in the peer-reviewed journal Royal Society Open Science, represent a promising development in efforts to monitor a disease that has severely affected Tasmanian devil populations for three decades. Researchers are investigating whether the technology can reliably detect the cancers before visible tumours develop, building on preliminary findings that suggest earlier detection may be possible.
The Challenge of Detecting Devil Facial Tumour Disease
Devil facial tumour disease (DFTD) is caused by two independently arising transmissible cancers that spread between Tasmanian devils through the transfer of living cancer cells, primarily during biting associated with fighting and mating.
The first cancer, DFT1, was recorded in north-eastern Tasmania in 1996 and has since spread across much of the state. A second cancer, DFT2, was identified in 2014 and has remained largely confined to the D’Entrecasteaux Channel region in southern Tasmania.
Both cancers produce aggressive tumours, commonly around the mouth, face and neck. As the disease progresses, affected animals can struggle to feed, with death typically occurring within months of tumours becoming visible. According to Tasmania’s Department of Natural Resources and Environment, devil populations in some disease-affected areas have declined by up to 80 per cent.

Disease monitoring has traditionally relied on identifying visible tumours during wildlife surveys, while laboratory techniques, including genetic testing, are used to confirm diagnoses and distinguish between DFT1 and DFT2. These methods provide valuable information but are less suited to rapid testing in remote field locations, where samples may need to be transported for analysis.
How the New Test Works
Developed by researchers at the University of Tasmania’s Menzies Institute for Medical Research, the test uses a molecular technique known as SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing). It combines DNA amplification with CRISPR-based technology to recognise genetic sequences associated with the two transmissible cancers.
When the targeted DNA is present, the system activates a fluorescent signal that can be detected using portable equipment. The researchers demonstrated that the method could identify extremely small quantities of DNA from both DFT1 and DFT2 under laboratory conditions.
The test can also be performed using oral swabs, allowing samples to be collected without taking tumour biopsies. The method uses isothermal DNA amplification, which avoids the repeated heating and cooling cycles required by conventional PCR and reduces the equipment needed for field testing.
Field Testing Detects DFT1 in Wild Devils
The researchers demonstrated that the diagnostic method could identify DFT1 using swab samples collected under field conditions, establishing that the technology could operate outside a conventional laboratory.
Earlier testing had also produced encouraging findings. In a 2024 University of Tasmania research presentation, the team reported detecting DFT1 in seven devils with visible tumours, as well as one devil without a visible tumour. This preliminary result suggested the possibility of detecting tumour DNA before visible symptoms develop, although the animal’s disease status would need to be independently confirmed.
Research has since expanded. At a scientific conference in March 2026, lead researcher Anuk Kruawan reported that the team had tested more than 300 swab samples collected from 114 wild Tasmanian devils across the state. The researchers described high diagnostic sensitivity and specificity, with relatively few false-positive and false-negative results.
However, these conference findings should be distinguished from the results confirmed in the newly published peer-reviewed paper. Further validation is needed to establish how consistently the test identifies disease in animals without visible tumours and whether it can be used reliably for routine surveillance.
Why Earlier Detection Matters
By the time facial tumours become visible, the cancer may already be well established. This presents a challenge for researchers monitoring wild populations, particularly when animals are captured and examined only periodically.
A diagnostic test capable of identifying disease at an earlier stage could help researchers investigate how infections develop and spread between animals. It could also provide more accurate information about the distribution of DFT1 and DFT2, particularly in areas where regular monitoring is difficult.
Earlier diagnosis may also help researchers investigate differences in disease progression between individual devils, including why some animals survive longer than others. The preliminary detection of DFT1 in an animal without a visible tumour provides a reason to investigate this possibility further, although repeated testing and independent confirmation would be needed to establish its diagnostic value.
Supporting Future Vaccine Research
The new diagnostic test could also support ongoing efforts at the University of Tasmania to develop a vaccine against devil facial tumour disease.
Researchers at the Menzies Institute for Medical Research are developing an oral bait vaccine intended to protect wild Tasmanian devils without requiring each animal to be captured for vaccination. The project aims to develop protection against both DFT1 and DFT2, with field trials planned to assess its effectiveness.
Reliable field testing could help researchers monitor disease prevalence and evaluate vaccination outcomes, particularly by identifying whether vaccinated animals subsequently develop tumours. However, the vaccine remains under development, and its effectiveness in protecting wild devils has not yet been established.
Improving Tasmanian Devil Disease Surveillance
The development of a portable diagnostic test offers researchers another way to monitor devil facial tumour disease, alongside existing wildlife surveys and laboratory testing. Its ability to detect DFT1 in field-collected samples is an important step towards making molecular disease surveillance more accessible in remote areas.
The next challenge will be establishing how reliably the test performs across larger populations and whether it can become a practical part of routine wildlife disease monitoring.
Editorial Note: This article is based on research published in Royal Society Open Science on 11 November 2026, supported by earlier University of Tasmania research presentations, peer-reviewed studies and information from Tasmania’s Department of Natural Resources and Environment. Preliminary conference findings are identified separately from the published study’s confirmed results.
Cover Image by Kunal Kalra / Unsplash

